Lilly Begins Efficacy Study For Inhaled Insulin
This article was originally published in The Pink Sheet Daily
Executive Summary
The non-inferiority study is the third part of Lilly and Alkermes' "comprehensive" clinical program.
You may also be interested in...
Waiting to Exhale: Lilly Inhaled Insulin NDA Filing Will Wait For Safety Data
Phase III AIR safety study, which recently completed enrollment, will last 24 months.
Waiting to Exhale: Lilly Inhaled Insulin NDA Filing Will Wait For Safety Data
Phase III AIR safety study, which recently completed enrollment, will last 24 months.
Novo Nordisk Inhaled Insulin To Resume Phase III Studies
Trials for the AERx inhaled insulin system will involve both type 1 and type 2 diabetes, despite a previous safety signal in type 1 patients.